Abstract
The present disclosure relates to (4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1Hcyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl) acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl) pyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indazol3-yl)(methylsulfonyl)amide Sodium, is represented by following structural formula (1) and its process for the preparation thereof.
The present disclosure relates to 2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3, 4]cyclopenta[1, 2-c]pyrazol-1-yl)acetic acid is represented by following structural formula (2) and its process for the preparation thereof.
The present disclosure relates to (S)-tert-butyl (1-(3-bromo-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)carbamate is represented by following structural formula (3) and its process for the preparation thereof.
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Recommended Citation
Lee Pharma Limited, "AN IMPROVED PROCESS FOR THE PREPARATION OF AN INTERMEDIATES OF (4-CHLORO-7-(2-((S)-1-(2-((3BS,4AR)-5,5-DIFLUORO-3- (TRIFLUOROMETHYL) -3B,4,4A,5-TETRAHYDRO-1HCYCLOPROPA [3,4]CYCLOPENTA[1,2-C]PYRAZOL-1-YL)ACETAMIDO)-2-(3,5-DIFLUOROPHENYL)ETHYL)-6-(3-METHYL-3-(METHYLSULFONYL) BUT-1-YN-1-YL)PYRIDIN-3-YL)-1-(2,2,2-TRIFLUOROETHYL)-1H-INDAZOL3-YL)(METHYLSULFONYL)AMIDE SODIUM", Technical Disclosure Commons, ()
https://www.tdcommons.org/dpubs_series/11773